Gerson R, Serrano A, Flores F, Villalobos A

Language: Spanish
References: 22
Page: 171-175
PDF size: 45.78 Kb.

ABSTRACT

Background: Ovarian epithelial cancer occups the fourth site among neoplasms of women and the seventh like cause of death from cancer. Recurrence and survival are depending of initial staging and the feasibility for performing an optimal debulking. Paclitaxel plus carboplatin is chemotherapy scheme considered as fisrt line of treatment. New drugs are investigated for treating this disease Objectives: To analyze the efficacy and security of gemcitabine in patients with pretreated, advanced epithelial ovarian cancer. Patients and methods: Women with confirmed diagnosis of epithelial ovarian cancer, advanced stages, with persistence or recurrence to other chemotherapy schemes, follow-up › 6 months. Who received 2 or more cycles of gemcitabine were considered by response analysis and for toxicity analysis with at leats 1 cycle. Gemcitabine 1000 mg/m² weekly during 3 weeks and one of rest. Age, stage, Karnofsky scale, therapeutic response, duration, time to progression disease and overall survival were registered. Results: From February 1996 to June 2003 ten patients were included, mean age 56.9 years, range 36 to 65. Four cases with papillar carcinoma, endometrioid 3, poorly differentiated adenocarcinoma 2 and micropapillar 1. Stage IIIA in 3 cases and IIIB in 7. Optimal surgery in 3 and suboptimal in 7 patients. Nine cases developed recurrence at abdominal cavity and 1 to pleural space. Gemcitabine was applied like second line to 6 patients (60%), third in 2, fourth in 1 and fifth in 1. Mean gemcitabine cycles/patient 4.2, range 1 to 13. We observed 1 complete and 3 partial responses, response rate 40%. Mean duration of response 8.2 months, range 3 to 17. Four deaths were registered during the study, all of them because of progression of disease. Conclusions: Gemcitabine is an active drug for the pretreated, advanced, epithelial ovarian cancer; their administration does not is related to severe side effects, which allow to maintain an adequate quality of life. Evaluation of this drug in association to another active antineoplastic drugs for epithelial ovarian cancer are required.

REFERENCES

1. Dirección General de Epidemiología. Registro Histopatológico de Neoplasias en México 1998. Dirección General de Epidemiología, Secretaría de Salud.

2. Gerson R, Serrano A, Villalobos A. Registro diario de consulta 2002 y 2003 (comunicación personal).

3. Ozols RF, Schwartz PE, Eifel PJ. Ovarian cancer, fallopian tube carcinoma and peritoneal carcinoma. In De Vita V Jr, Hellman S, Rosemberg SA (eds). Cancer: Principles and practice of the neoplasms. 5th ed. Philadelphia, PA: Lippincott, 2002; 1597–1632.

4. McGuire WF, Hoskins WI, Brady MF et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. New Engl J Med 1996; 334: 1-6.

5. Ozols RF, Bundy BN, Geer BE et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer. J Clin Oncol 2003; 21: 3194–3200.

6. Markman M. Second-lined treatment of ovarian cancer with single agent gemcitabine. Sem Oncol 2002; 29 (supl 1): 9–10.

7. Morhan-Ihring C, Lembersky B, Christopherson W et al. A phase II evaluation of difluorodeoxycytidine in advanced stage refractory ovarian cancer. Proc ASCO 1995; A196.

8. Kudelka AP, Verschaegen CF, Edwards CL et al. A preliminary report of a phase 2 study of gemcitabine in women with platinum refractory mullerian (ovarian, fallopian tube and primary peritoneal) carcinomas. Proc ASCO 2000; 20: A1415.

9. Gebauer G, Jager W, Lang N. Gemcitabine chemotherapy in heavely pre-treated patients with recurrent ovarian cancer. J Cancer Res Clin Oncol 1999; 125 (supl): S88.

10. Coenen M, Bertellot P, Armant F et al. Gemcitabine in platin-paclitaxel resistant ovarian cancer. Proc ASCO 20002; A1603.

11. Friedlander M, Millward MJ, Bell D et al. A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer. Ann Oncol 1998; 9: 1343-1345.

12. Lund B, Hansen OP, Theilade K et al. Phase II study of gemcitabine in previously treated ovarian cancer patients. J Natl Cancer Inst 1994; 86: 1530-1533.

13. Markman M, Kennedy A, Webster K et al. Phase II trial of single agent gemcitabine in platinum/paclitaxel refractory ovarian cancer. Proc ASCO 2001; A813.

14. Shapiro JD, Millward MJ, Rischin D et al. Activity of gemcitabine in patients with advanced ovarian cancer: Responses seen following platinum and paclitaxel. Gynecol Oncol 1996; 63: 89-93.

15. Underhill C, Parnis FX, Highley MS et al. Multicenter phase II study gemcitabine in previously untreated patients with advanced epithelial ovarian cancer. Anticancer Drugs 2001; 12: 647-652.

16. Von Minckwitz G, Bauknecht T, Visseren-Grul CM et al. Phase II study of gemcitabine in ovarian cancer. Ann Oncol 1999; 10: 853-855.

17. Silver DF, Piver MS. Gemcitabine salvage chemotherapy for patients with gynaecologic malignancies of the ovary, fallopian tube and peritoneum. Am J Clin Oncol 1999; 22: 450-452.

18. Velasco A, Pérez M. Gemcitabine and cisplatin treatment for patients with platinum resistant ovarian cancer and as consolidation treatment of patients with residual disease after first line chemotherapy. Proc ASCO 2001; A2477.

19. Ruíz G, Alexander F, Rodríguez G et al. Gemcitabine plus cisplatin as first line therapy for advanced ovarian cancer. Proc ASCO 2002; A852.

20. Belpome D, Krakowk I, Beaudin M et al. Gemcitabine combined with cisplatin is active and feasible as first line treatment in patients with advanced epithelial ovarian cancer. Proc ASCO 2002; A888.

21. Roman L, García AA, Facio G et al. Phase II study of weekly paclitaxel and gemcitabine in platinum resistant ovarian cancer. Proc ASCO 2001; A877.

22. Salimi-chokami M, Aminian S. Weekly gemcitabin and docetaxel a novel second line regimen in recurrent platinum resistant epithelial ovarian cancer a phase II study. Proc ASCO 2002; A2537.